Comparative Pharmacology
Head-to-head clinical analysis: TIAZAC versus VASCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIAZAC versus VASCOR.
TIAZAC vs VASCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
VASCOR (bepridil) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, reducing contractility and oxygen demand. It also has class I and IV antiarrhythmic properties.
Oral: 120-360 mg once daily; maximum 540 mg daily.
Bepridil hydrochloride (Vascor) is typically dosed as 200 mg to 400 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Terminal elimination half-life: 6-8 hours (normal renal/hepatic function). May be prolonged in hepatic impairment; unchanged in renal impairment.
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Primarily hepatic metabolism; ~70% excreted in feces as metabolites, ~30% in urine (largely as metabolites). <2% excreted unchanged in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker